Subject(s)
Antiviral Agents , COVID-19 Drug Treatment , COVID-19 , Viral Load , Adult , Aged , Female , Humans , Male , Middle Aged , Administration, Oral , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , COVID-19/therapy , SARS-CoV-2 , Viral Load/drug effectsABSTRACT
WHAT IS KNOWN AND OBJECTIVE: Erenumab is a monoclonal antibody for the prophylactic treatment of migraine. We describe the first cases of xerostomia probably induced by this drug. CASE SUMMARY: We present two patients diagnosed with chronic migraine who started treatment with erenumab and presented with dry mouth after the first and second dose. WHAT IS NEW AND CONCLUSION: Xerostomia is not described as an adverse reaction in the drug's technical datasheet. A search was made in PubMed including 'erenumab', 'fremanezumab', 'galcanezumab', 'xerostomia', and no results were found. It is necessary to identify this potential adverse reaction in order to estimate its prevalence and possible impact on patients' quality of life.
Subject(s)
Migraine Disorders , Xerostomia , Antibodies, Monoclonal, Humanized , Calcitonin Gene-Related Peptide Receptor Antagonists/adverse effects , Humans , Migraine Disorders/drug therapy , Migraine Disorders/prevention & control , Quality of Life , Xerostomia/chemically inducedABSTRACT
Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk test (10MWT), nine-hole peg test (9HPT) and handgrip strength measurement using a handheld Jamar dynamometer. Results: Regarding muscular and motor functions associated with higher inflammation and oxidation, improvements only observed in the woman in all analysed parameters (both biochemical and clinical associated with the metabolism and functionality) after 4 months of treatment with EGCG are noteworthy. Thus, this treatment is proposed as a good candidate to treat the disease.
Subject(s)
Catechin/analogs & derivatives , Charcot-Marie-Tooth Disease , Aryldialkylphosphatase , Charcot-Marie-Tooth Disease/drug therapy , Female , Hand Strength , Humans , Male , Walk TestABSTRACT
Introduction: Alzheimer's disease is one of the most prevalent neurodegenerative dementia in developed world. This fact, coupled with the lack cure, makes new no pharmacological therapeutic strategies such as nutrient management to investigate. In this regard, it stresses the possible influence of coconut oil as alternative energy source capable of stopping the progressively neuronal death that occurs in this disease. Objectives: To assess the cognitive impact of coconut oil in Alzheimer's patients, and specifically in orientation, language-building, fixing, calculation-concentration and memory areas. Methods: Prospective, longitudinal, qualitative, analytical and experimental study through a clinical trial where 44 patients with Alzheimer's in region of Ribera (Valencia), of which half was selected to receive during 21 days, 40 ml coconut oil daily divided between breakfast (20 ml) and food (20 ml). Before and after administration of the oil, they were evaluated through cognitive test Mini-Mental State Examination to determine possible changes. Results: It was observed in patients who received coconut oil, that cognitive improvement after completion of the intervention, statistically significant improved in the orientation and language-construction areas. Conclusions: Coconut oil appears to improve cognitive abilities of Alzheimer's patients, with different intensity depending on the cognitive area.
Introducción: la enfermedad de Alzheimer es a día de hoy la demencia neurodegenerativa con mayor prevalencia en el primer mundo. Este hecho, unido a la falta de tratamiento farmacológico que cure la enfermedad, hace que se estudien nuevas estrategias terapéuticas no farmacológicas como es la administración de nutrientes. En este sentido, destaca la posible influencia del aceite de coco como fuente energética alternativa, capaz de frenar la muerte neuronal que se produce de modo progresivo en esta enfermedad. Objetivos: valorar el impacto del aceite de coco a nivel cognitivo en pacientes de alzhéimer, y concretamente en las áreas de orientación, lenguaje-construcción, fijación, cálculo-concentración y memoria. Métodos: estudio prospectivo, longitudinal, cualitativo, analítico y experimental a través de un ensayo clínico, donde se seleccionaron a 44 pacientes con alzhéimer de la zona de la Ribera (Comunidad Valenciana), de los cuales a la mitad se le administró durante 21 días, 40 ml diarios de aceite de coco repartidos entre desayuno (20 ml) y comida (20 ml). Antes y después de la administración del aceite, se les valoró a través del test cognitivo Mini-Examen Cognoscitivo, para determinar los posibles cambios. Resultados: en los enfermos que tomaron el aceite de coco se observó una mejora cognitiva tras finalizar la intervención, siendo estadísticamente significativa en las áreas de orientación y lenguaje-construcción. Conclusiones: el aceite de coco parece mejorar la capacidad cognitiva de los enfermos de alzhéimer, variando la intensidad de la misma en función del área cognitiva.
Subject(s)
Alzheimer Disease/drug therapy , Alzheimer Disease/psychology , Coconut Oil/therapeutic use , Cognition/drug effects , Aged , Aged, 80 and over , Female , Humans , Longitudinal Studies , Male , Memory , Orientation/drug effects , Prospective Studies , Psychomotor Performance/drug effects , Verbal Learning/drug effectsABSTRACT
Introducción: la enfermedad de Alzheimer es a día de hoy la demencia neurodegenerativa con mayor prevalencia en el primer mundo. Este hecho, unido a la falta de tratamiento farmacológico que cure la enfermedad, hace que se estudien nuevas estrategias terapéuticas no farmacológicas como es la administración de nutrientes. En este sentido, destaca la posible influencia del aceite de coco como fuente energética alternativa, capaz de frenar la muerte neuronal que se produce de modo progresivo en esta enfermedad. Objetivos: valorar el impacto del aceite de coco a nivel cognitivo en pacientes de alzhéimer, y concretamente en las áreas de orientación, lenguaje-construcción, fijación, cálculo-concentración y memoria. Métodos: estudio prospectivo, longitudinal, cualitativo, analítico y experimental a través de un ensayo clínico, donde se seleccionaron a 44 pacientes con alzhéimer de la zona de la Ribera (Comunidad Valenciana), de los cuales a la mitad se le administró durante 21 días, 40 ml diarios de aceite de coco repartidos entre desayuno (20 ml) y comida (20 ml). Antes y después de la administración del aceite, se les valoró a través del test cognitivo Mini-Examen Cognoscitivo, para determinar los posibles cambios. Resultados: en los enfermos que tomaron el aceite de coco se observó una mejora cognitiva tras finalizar la intervención, siendo estadísticamente significativa en las áreas de orientación y lenguaje-construcción. Conclusiones: el aceite de coco parece mejorar la capacidad cognitiva de los enfermos de alzhéimer, variando la intensidad de la misma en función del área cognitiva (AU)
Introduction: Alzheimers disease is one of the most prevalent neurodegenerative dementia in developed world. This fact, coupled with the lack cure, makes new no pharmacological therapeutic strategies such as nutrient management to investigate. In this regard, it stresses the possible influence of coconut oil as alternative energy source capable of stopping the progressively neuronal death that occurs in this disease. Objectives: To assess the cognitive impact of coconut oil in Alzheimers patients, and specifi cally in orientation, language-building, fixing, calculation-concentration and memory areas. Methods: Prospective, longitudinal, qualitative, analytical and experimental study through a clinical trial where 44 patients with Alzheimers in region of Ribera (Valencia), of which half was selected to receive during 21 days, 40 ml coconut oil daily divided between breakfast (20 ml) and food (20 ml). Before and after administration of the oil, they were evaluated through cognitive test Mini-Mental State Examination to determine possible changes. Results: It was observed in patients who received coconut oil, that cognitive improvement after completion of the intervention, statistically significant improved in the orientation and language-construction areas. Conclusions: Coconut oil appears to improve cognitive abilities of Alzheimers patients, with different intensity depending on the cognitive area (AU)
Subject(s)
Humans , Male , Female , Alzheimer Disease/diet therapy , Cognition Disorders/diet therapy , Palm Oil/prevention & control , Vegetable Fats , Nutrients , Ketone Bodies/therapeutic use , Prospective Studies , Longitudinal Studies , 25783 , Surveys and QuestionnairesABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Purpura, Thrombotic Thrombocytopenic/chemically induced , Purpura, Thrombotic Thrombocytopenic/complications , Transplantation, Homologous/methods , Hemolysis , Immunosuppressive Agents/therapeutic use , Tacrolimus/therapeutic use , Hepatic Veno-Occlusive Disease/blood , Hepatic Veno-Occlusive Disease/complications , Leukemia, Lymphoid/complications , Platelet Count/methodsABSTRACT
BACKGROUND: Alzheimer's dementia is the most prevalent nowadays. As for treatment, there is no definitive cure drug, thus new therapies are needed. In this regard the medium chain triglycerides are a direct source of cellular energy and can be a nonpharmacological alternative to the neuronal death for lack of it, that occurs in Alzheimer patients. OBJECTIVE: to evaluate the impact of coconut oil in the development of Alzheimer's dementia, in any degree of dementia. Also determine whether this improvement influences within variables such as sex and suffering or not Type II Diabetes Mellitus. MATERIAL AND METHODS: a prospective study was conducted in patients with Alzheimer's dementia, with a control and an intervention group which was administered 40 ml/day of extra virgin coconut oil. The parameters evaluated were the mini test scores Lobo cognitive test, pre and post intervention in both groups. RESULTS: it was observed in subjects taking the product, a statistically significant increase in test score MECWOLF and therefore an improvement in cognitive status, improving especially women's, those without diabetes mellitus type II, and severe patients. CONCLUSION: this study, although preliminary, demonstrated the positive influence of coconut oil at the cognitive level of patients with Alzheimer's, this improvement being dependent on sex, presence or absence of diabetes and degree of dementia.
Introducción: la enfermedad de Alzheimer es la demencia más prevalente en la actualidad. En cuanto al tratamiento, no existe cura farmacológica definitiva, con lo cual son necesarias nuevas alternativas terapéuticas. En este sentido, los triglicéridos de cadena media suponen una fuente directa de energía celular y pueden ser una alternativa no farmacológica a la muerte neuronal por falta de la misma, que se produce en los enfermos de Alzheimer. Objetivo: evaluar el impacto que tiene el aceite de coco en la evolución de la demencia tipo Alzheimer, en cualquier grado de demencia. Asimismo, determinar si existe influencia en dicha mejora, de variables como el sexo y padecer o no diabetes mellitus tipo II. Material y métodos: estudio prospectivo realizado en pacientes con demencia tipo Alzheimer, con un grupo control y un grupo de intervención al que se le administró 40 ml/día de aceite de coco virgen extra. Los parámetros evaluados han sido las puntuaciones del test del miniexamen cognoscitivo de Lobo, pre y postintervención en ambos grupos. Resultados: se observó en los sujetos que tomaban el producto un aumento estadísticamente significativo de la puntuación del test MEC-LOBO y, por consiguiente, una mejoría del estado cognitivo, mejorando sobre todo las mujeres, los que no tenían diabetes mellitus tipo II y los pacientes graves. Conclusión: este estudio, aunque preliminar, demuestra la influencia positiva del aceite de coco a nivel cognitivo en los pacientes con Alzheimer, siendo esta mejoría dependiente del sexo, de la existencia o no de diabetes y del grado de demencia.
Subject(s)
Alzheimer Disease/prevention & control , Plant Oils/therapeutic use , Aged , Aged, 80 and over , Alzheimer Disease/psychology , Coconut Oil , Cognition/drug effects , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Prospective StudiesABSTRACT
Objetivo: estudiar el perfil de efectividad y seguridad de abiraterona en la práctica clínica, en pacientes con cáncer de próstata metastásico hormonoresistente. Métodos: se diseñó un estudio descriptivo retrospectivo de los pacientes diagnosticados con cáncer de próstata metastásico que recibieron tratamiento con abiraterona durante los mese de febrero 2012 a abril 2013. Las variables estudiadas fueron sexo, edad, escala del Eastern Cooperative Oncology Group (ECOG), tratamiento previo con docetaxel, antígeno prostático especifico (PSA) y supervivencia libre de progresión. La información se obtuvo de las historias clínicas, el programa de prescripción Savac® y el programa de validación farmacéutica FarmisâOncofarm®. Resultados: los 24 pacientes incluidos contaban una mediana de edad de 70 años. El estado funcional fue ECOG<2 en el 58,3 por ciento y ECOG≥2 en el 41,7 por ciento de los pacientes. El PSA disminuyó un 50 por ciento o más de su valor basal en el 52 por ciento de los pacientes. En cuanto a la supervivencia libre de progresión la mediana fue de 166 días (5,5 meses). En los pacientes con un ECOG≤2 la mediana fue de 231 días (7,7 meses) mientras que para los pacientes con ECOGË2 fue de 106 días (3,5 meses). Abiraterona presentó pocas reacciones adversas por lo que resulta un fármaco seguro, a pesar de presentar algunas reacciones de suma importancia. Conclusiones: los resultados obtenidos en nuestra práctica clínica difieren con los obtenidos en los estudios pivotales. Se observan mayor supervivencia libre de progresión en los pacientes con un ECOG≤1 y en los que nunca habían recibido quimioterapia previa(AU)
Objectives: to study the efficacy and safety profile of abiraterone in clinical practice to treat patients with hormone-resistant metastatic prostate cancer. Methods: retrospective and descriptive study of patients who were diagnosed with metastatic prostate cancer and were treated with abiraterone since February 2012 to April 2013. The studied variables were gender, age, level of Eastern Cooperative Oncology Group (ECOG) scale, prior treatment with docetaxel, prostate specific antigen (PSA), progression-free survival (PFS). Data sources included medical records, the Savac® prescription and the Farmis-Oncofarm® pharmaceutical validation programs. Results: twenty-four patients were included, with average age of 70 years. The ECOG performance status was less than 2 in 58,3 percent of patients whereas 41,7 percent of the patients showed ECOG equal to 2 or higher. The PSA decreased by 50 percent or more its basal value in 52 percent of the patients. As regards to PFS, the median was 166 days (5,5 months) in progression-free survival. In patients with ECOG≤2, the median PFS was 231 days (7,7 months), whereas for patients with ECOGË2,it was 106 days (3,5 months). Abiraterone has fewer side effects, so it may be considered a safe drug, although some are significant. Conclusions: the results obtained in our clinical practice differ from the ones obtained in the pivotal trials . Increased progression-free survival was observed in patients with an ECOG≤1 or less, and in those who had never received prior chemotherapy(AU)
Subject(s)
Humans , Male , Prostatic Neoplasms/drug therapy , Abiraterone Acetate/therapeutic use , Spain , Epidemiology, Descriptive , Retrospective StudiesABSTRACT
Introducción: la enfermedad de Alzheimer es la demencia más prevalente en la actualidad. En cuanto al tratamiento, no existe cura farmacológica definitiva, con lo cual son necesarias nuevas alternativas terapéuticas. En este sentido, los triglicéridos de cadena media suponen una fuente directa de energía celular y pueden ser una alternativa no farmacológica a la muerte neuronal por falta de la misma, que se produce en los enfermos de Alzheimer. Objetivo: evaluar el impacto que tiene el aceite de coco en la evolución de la demencia tipo Alzheimer, en cualquier grado de demencia. Asimismo, determinar si existe influencia en dicha mejora, de variables como el sexo y padecer o no diabetes mellitus tipo II. Material y métodos: estudio prospectivo realizado en pacientes con demencia tipo Alzheimer, con un grupo control y un grupo de intervención al que se le administró 40 ml/día de aceite de coco virgen extra. Los parámetros evaluados han sido las puntuaciones del test del miniexamen cognoscitivo de Lobo, pre y postintervención en ambos grupos. Resultados: se observó en los sujetos que tomaban el producto un aumento estadísticamente significativo de la puntuación del test MEC-LOBO y, por consiguiente, una mejoría del estado cognitivo, mejorando sobre todo las mujeres, los que no tenían diabetes mellitus tipo II y los pacientes graves. Conclusión: este estudio, aunque preliminar, demuestra la influencia positiva del aceite de coco a nivel cognitivo en los pacientes con Alzheimer, siendo esta mejoría dependiente del sexo, de la existencia o no de diabetes y del grado de demencia (AU)
Background: Alzheimers dementia is the most prevalent nowadays. As for treatment, there is no definitive cure drug, thus new therapies are needed. In this regard the medium chain triglycerides are a direct source of cellular energy and can be a nonpharmacological alternative to the neuronal death for lack of it, that occurs in Alzheimer patients. Objective: to evaluate the impact of coconut oil in the development of Alzheimers dementia, in any degree of dementia. Also determine whether this improvement influences within variables such as sex and suffering or not Type II Diabetes Mellitus. Material and methods: a prospective study was conducted in patients with Alzheimers dementia, with a control and an intervention group which was administered 40 ml/day of extra virgin coconut oil. The parameters evaluated were the mini test scores Lobo cognitive test, pre and post intervention in both groups. Results: it was observed in subjects taking the product, a statistically significant increase in test score MECWOLF and therefore an improvement in cognitive status, improving especially womens, those without diabetes mellitus type II, and severe patients. Conclusion: this study, although preliminary, demonstrated the positive influence of coconut oil at the cognitive level of patients with Alzheimers, this improvement being dependent on sex, presence or absence of diabetes and degree of dementia (AU)
Subject(s)
Humans , Alzheimer Disease/diet therapy , Palm Oil/analysis , Evaluation of Results of Therapeutic Interventions , Prospective Studies , Case-Control Studies , Diabetes Mellitus, Type 2/epidemiology , Ketone Bodies/metabolism , Triglycerides/analysisABSTRACT
Objetivo: Conhecer a taxa de contaminação de hemoculturas e os seus fatores determinantes. Métodos: Foram analisadas 564 amostras de hemoculturas requisitadas num serviço hospitalar de urgências e questionados 46 enfermeiras(os) durante um período de seis meses. Resultados: Produziram-se 92 contaminações de hemoculturas de um total de 564 requisições num período de seis meses, o que corresponde a uma taxa de contaminação de 16,31%. O fator determinante foi a utilização de técnica pouco estéril. Conclusão: A taxa de contaminação das hemoculturas está diretamente relacionada aos procedimentos utilizados pelos profissionais de enfermagem e a carga de trabalho está diretamente associada a erros na técnica estéril de coleta. .
Objective: Determining the contamination rate of blood cultures and its determining factors. Methods: During a period of six months, were analyzed 564 blood culture samples requested at hospital emergency wards and 46 nurses were inquired. Results: In a period of six months, among a total of 564 requests, 92 blood cultures were contaminated, which corresponds to a contamination rate of 16.31%. The determining factor was the use of low-level sterile technique. Conclusion: The contamination rate of blood cultures is directly related to the procedures used by the nursing staff, and the workload is directly related to errors in the sterile technique of collection. .
